229 related articles for article (PubMed ID: 31528768)
1. Ocular adverse events with immune checkpoint inhibitors.
Fang T; Maberley DA; Etminan M
J Curr Ophthalmol; 2019 Sep; 31(3):319-322. PubMed ID: 31528768
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
Ebinama U; Sheshadri A; Anand K; Swaminathan I
J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
Fan Q; Chen H; Hu Y; Zhao B
Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
[TBL] [Abstract][Full Text] [Related]
4. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.
Kong Q; Wang H; Ren X; Zhuo Y; Peng J
Cancer Med; 2023 Oct; 12(19):19491-19499. PubMed ID: 37724594
[TBL] [Abstract][Full Text] [Related]
5. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
[TBL] [Abstract][Full Text] [Related]
7. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
9. Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data.
Abrahao A; Tenório PHM; Rodrigues M; Mello M; Nascimento OJM
BMJ Neurol Open; 2024; 6(1):e000544. PubMed ID: 38501128
[No Abstract] [Full Text] [Related]
10. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Chen G; Qin Y; Fan QQ; Zhao B; Mei D; Li XM
Cancer Med; 2020 Sep; 9(18):6576-6585. PubMed ID: 32720449
[TBL] [Abstract][Full Text] [Related]
11. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database.
Ruggiero R; Fraenza F; Scavone C; di Mauro G; Piscitelli R; Mascolo A; Ferrajolo C; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Pharmacol; 2020; 11():830. PubMed ID: 32581796
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
[TBL] [Abstract][Full Text] [Related]
14. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.
Xia S; Gong H; Wang YK; Liu L; Zhao YC; Guo L; Zhang BK; Sarangdhar M; Noguchi Y; Yan M
Front Pharmacol; 2023; 14():1129730. PubMed ID: 37007042
[No Abstract] [Full Text] [Related]
17. Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports.
Khurana A; Dubey H; Arora MK
Curr Drug Saf; 2024 Jan; ():. PubMed ID: 38310553
[TBL] [Abstract][Full Text] [Related]
18. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
19. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
